000			04228nam a22004335i 4500
999			_c10673 _d10673
001			10673
003			DE-He213
005			20210615040626.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			180313s2018 gw | s |||| 0|eng d
020			_a9783319735856
024	7		_a10.1007/978-3-319-73585-6 _2doi
040			_aES-MaUEC _bspa _dES-VaUE
050		4	_aRC935 .M93 _b2018 EB
245	1	0	_aMyasthenia Gravis and Related Disorders _cedited by Henry J. Kaminski, Linda L. Kusner.
250			_a3rd edition
264		1	_aCham _bSpringer International Publishing : _bImprint: Humana Press _c2018.
300			_a1 recurso en línea (XIII, 353 páginas 52 ilustraciones, 15 ilustraciones a color)
336			_2rdacontent _aTexto (visual) _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aCurrent Clinical Neurology _x1559-0585
490	0		_aMedicine (Springer-11650)
505	0		_aChapter 1. Neuromuscular Junction Physiology and Pathophysiology -- Chapter 2. Acetylcholine Receptor Structure -- Chapter 3. Immunopathogenesis of Myasthenia Gravis -- Chapter 4. Animal Models of Myasthenia Gravis for Preclinical Evaluation -- Chapter 5. Epidemiology and Genetics of Myasthenia Gravis -- Chapter 6. Clinical Presentations of Myasthenia Gravis -- Chapter 7. Ocular Myasthenia -- Chapter 8. Thymoma-associated Myasthenia Gravis -- Chapter 9. Electrodiagnosis of Neuromuscular Junction Disorders -- Chapter 10. Autoantibody Testing in the Diagnosis and Management of Autoimmune Disorders of Neuromuscular Transmission and Related Diseases -- Chapter 11. Treatment of Myasthenia Gravis -- Chapter 12. Neurocritical Care of Myasthenic Crisis -- Chapter 13. Thymectomy for Non-thymomatous Myasthenia Gravis -- Chapter 14. Lambert-Eaton Syndrome -- Chapter 15 Acquired Neuromyotonia -- Chapter 16. Congenital Myasthenic Syndromes -- Chapter 17. Toxic Neuromuscular Transmission Disorders -- Chapter 18. Predictors of Psychological Health in Myasthenia Gravis -- Chapter 19. Myasthenia Gravis: Classification and Outcome Measurements -- Chapter 20. Emerging Therapeutics for Myasthenia Gravis -- Chapter 21. Clinical Trial Design for Myasthenia Gravis.
520	3		_aThe third edition of this important, gold-standard title outlines a range of significant advances in the study and understanding of myasthenia gravis. The overarching goal of this new edition is identical to the first and second -- to provide the clinician and the scientist with a common resource for understanding the profound achievements in the clinical, translational, and basic sciences of neuromuscular transmission disorders. In addition to several new authors and an extensive update of all chapters, this third edition includes summaries of pre-clinical research standards for autoimmune MG, along with a broad summary of MG clinical trial performance. The now greater understanding of the clinical presentation of MuSK-related MG and identification of potential new autoantigens, including LRP-4, is discussed. The development of treatment guidelines by groups in Japan, the United Kingdom, Germany, and an international consortium is also outlined. Myasthenia Gravis and Related Disorders, Third Edition, is an invaluable resource for meeting the many and varied needs of clinicians who treat patients with myasthenia gravis.
988			_aEBSPRINGER_2018
650		7	_aNeurología _9139040 _2embne
650		7	_aMiastenia grave _9667117 _2embne
700	1		_aKaminski, Henry J. _eeditor literario _0http://id.loc.gov/authorities/names/n2002016630 _0http://viaf.org/viaf/22368208 _988068
700	1		_aKusner, Linda L. _eeditor literario
710	2		_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _0http://viaf.org/viaf/148105729 _9106996
776	0	8	_iEdición impresa: _z9783319735849
776	0	8	_iEdición impresa: _z9783319735863
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-73585-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942			_2lcc _cLE
998			_db _feng _ggw _h0